CARsgen Therapeutics Holdings Limited (HK:2171), a Chinese developer of innovative CAR T-cell therapies, announced on Saturday that satricabtagene autoleucel (satri-cel, product code: CT041), an autologous CAR T-cell therapy product targeting Claudin18.2, has been included in the latest Commercial Health Insurance Innovative Drug List (CHIIDL) issued by the National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security (MOHRSS), for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) who have failed at least two prior lines of therapy.
The new list will officially take effect in January 2027.
The CHIIDL primarily covers innovative drugs that go beyond the 'basic coverage' mandate of the national basic medical insurance scheme and therefore cannot yet be included in the basic reimbursement list, but which are highly innovative, of significant clinical value, deliver substantial patient benefit, and are well suited to insurance coverage. It provides a payment basis for China's multi-tiered healthcare security system, including commercial health insurance and mutual medical aid.
According to CARSgen, satri-cel is the first CAR T-cell therapy product for solid tumors to be included in the CHIIDL since the list was established, marking an extension of the multi-tiered healthcare security system's support for CAR T-cell therapy from hematologic malignancies into solid tumors, which affect a considerably larger patient population.
CARsgen said that it is actively expanding satri-cel application in early-line treatment and perioperative treatment of cancer, including an ongoing Phase I clinical trial for pancreatic cancer adjuvant therapy in China, an IIT for consolidation treatment following adjuvant therapy in patients with resected G/GEJA and an IIT for sequential therapy following first-line treatment for G/GEJA.
Aelis Farma announces receipt of second positive safety recommendation for Down syndrome trial
Ambrosia Biosciences reports data on two oral small molecule programs at ObesityWeek 2026
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177